Thromboserin Ltd. is an ‘innovator’ research company and their mission is to focus primarily on preventing arterial thrombosis. TH001 was granted a US Patent in December 2015, giving them IP until 2030.
"We have always been impressed by the standard of the work delivered by the Niche team. In addition, the contracting process is simple and efficient, communication is open, frequent and proactive, with any issues getting resolved quickly and efficiently."
Thromboserin first approached Niche to create the Investigator's Brochure (IB) for their product, TH001. This was particularly challenging as the information provided by the original Sponsor was poor quality and in hard copy only. Niche's renowned expertise in the writing of IBs ensured the quick and effective delivery of this document which was used to inform Thromboserin’s Protocol and subsequently used to build their Clinical Trial Application. Niche also aided Thromboserin’s search for development partners to support the company in their clinical development.
When an Alzheimer's programme hit a wall after two negative Phase III trials, EVERSANA called on Niche to make sense of.
read moreNiche played a foundational role in securing EMA approval for Strimvelis, the world's first ex vivo autologous gene.
read moreNiche partnered with Erytech Pharma to rescue and rewrite substandard clinical study reports, delivering a high-quality.
read moreNiche provided DemeRx with end-to-end support to launch a pioneering ibogaine addiction trial, covering site.
read moreThe clinical evidence Niche helped generate for Funxional's novel anti-inflammatory compound FX125L proved compelling.
read moreNiche prepared the full regulatory package for HOOKIPA's groundbreaking arenavirus immunotherapy platform, enabling the.
read moreWhat began as a CSR writing request grew into a broad regulatory partnership, with Niche guiding iOnctura's roginolisib.
read moreRegulatory documentation, ILAP designation and a robust clinical protocol for the Sunlight Trial — Niche helped.
read moreFrom Phase I protocols to a full Marketing Authorisation Application, Niche was VectivBio's embedded regulatory writing.
read moreGet our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
